Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px
Organisation › Details

Horizon Discovery Group plc (LSE: HZD)

Horizon Discovery Limited (Horizon) is a leading provider of research tools to support translational genomics research and the development of personalized medicines. The Company's proprietary technology, GENESIS, is the world's most precise genome editing technology. Using GENESIS, Horizon is able to alter any endogenous gene sequence of a human or mammalian cell-line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes. Horizon has harnessed GENESIS to create over 400 X-MAN cell lines, the world's first source of genetically-defined and patient-relevant human cell lines, accurately modeling the disease-causing mutations found in cancer patients. These 'patients-in-a-test-tube' are being used by academic and industry leaders to identify the effect of individual genetic mutations on drug activity, patient responsiveness, and resistance, leading to the successful prediction of which patient sub-groups will respond to currently-available and future drug treatments. This enables the design of shorter, more focused, and less expensive clinical trials, ultimately providing the tools to identify the 'right drugs' for the 'right patients' based upon the unique genetic mutations that define their disease. In addition to the X-MAN cell lines, Horizon provides GENESIS and X-MAN derived products and services, with industrial application in: bio-pharmaceutical process optimization; clinical diagnostic development; drug discovery & development; and the provision of reference standards for genomic-based clinical research platforms. *

 

Period Start 2007-06-01 established
  Group Horizon Discovery (Group)
  Predecessor Horizon Discovery Ltd.
Product Industry drug discovery
Persons Person Disley, Darrin M. (Horizon Discovery 201109 CEO before Commercial Director)
  Person 2 Vellacott, Richard (Horizon Discovery 201207– CFO before VP Finance at CSR plc before Deloitte)
     
Region Region Waterbeach, Cambridgeshire
  Country United Kingdom (GB)
  City CB25 9TL Cambridge, Cambridgeshire
    Address record changed: 2016-07-24
     
Basic data Employees n. a.
  Currency GBP
  Annual sales 20,156,000 (revenue, consolidated (2015) 2015-12-31)
  Profit -9,883,000 (2015-12-31)
  Cash 25,067,000 (2015-12-31)
     
    * Document for »About Section«: 
     
   
Record changed: 2017-12-21

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 600x60px

More documents for Horizon Discovery (Group)


To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px